Johnson & Johnson announced that nipocalimaba was granted U.S. FDA Fast Track designation as a potential treatment for adults with systemic lupus erythematosus, a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $253 from $227 at BofA
- Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating
- KURE vs. VHT: Comparing China and U.S. Healthcare ETFs
- Boeing, Walmart, Coca-Cola, Ford, J&J: Insider Moves Exposed
- J&J posts early phase 1b results for pasritamig in metastatic prostate cancer